Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Zabadinostat · AZD-9468, CXD-101

Small molecule · Inhibitor of histone deacetylase (HDAC9) · developed by ImmunityBio

Phase 1 Most advanced trial (none active)
IBRX Developer
1 Registered trials

What is Zabadinostat?

Zabadinostat (CXD101) is a histone deacetylase (HDAC) inhibitor studied in pancreatic cancer. It inhibits HDAC catalytic activity, leading to accumulation of acetylated histones, chromatin remodeling, and altered gene expression patterns.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AZD-9468, CXD-101
Drug type
Small molecule
Targets
histone deacetylase (HDAC9)
Mechanism
Inhibitor of histone deacetylase (HDAC9)
Pathways
chromatin remodeling, gene expression
Therapy area
Oncology
Developer
ImmunityBio, Inc. (IBRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
5TNV87ICD2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07488884 Phase 1 Pancreatic Cancer Resectable Withdrawn IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic CancerPancreatic Cancer Resectable

Other drugs acting on HDAC9

CUDC-101 Phase 1 MTX110 Phase 1

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind Zabadinostat

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.